We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
KRAS: Druggable at Last.
- Authors
Herzberg, Benjamin O; Manji, Gulam A
- Abstract
The article deals with the approval granted by the U.S. Food and Drug Administration in December 2022 to adagrasib, a mutant-selective inhibitor of the Kirsten rat sarcoma viral homolog (KRAS), for the treatment of metastatic non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation after one prior therapy. Topics include information on KRAS, a key question about adagrasib and sotorasib, and significance of the approval of adagrasib to drug development and oncology.
- Subjects
THERAPEUTIC use of monoclonal antibodies; THERAPEUTIC use of antineoplastic agents; PROTEINS; DRUG approval; GENETIC mutation; ONCOGENES; LUNG tumors; ALLELES; CELLULAR signal transduction
- Publication
Oncologist, 2023, Vol 28, Issue 4, p283
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1093/oncolo/oyad014